Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Arvinas Reports First Quarter 2023 Financial Results and
–Multiple vepdegestrant (ARV-471) studies enrolling globally,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Arvinas
Arvinas to Present at Stifel Targeted Oncology Day
NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas,…
Arvinas to Participate in Upcoming Investor Conferences
<!-- Name:DistributionId Value:8743540 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Arvinas Announces Changes to its Board of Directors
NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A.,…